A genome research team at the Institute for Basic Science has succeeded in editing a specific mitochondrial deoxyribonucleic acid (DNA) sequence of a mouse using a DddA-derived cytosine base editor (DdCBE), the institute said Friday.The study is the world's first case of applying DdCBE to animals, a
Hugel said Friday it has won the sales approval for Letybo 50 Unit, its botulinum toxin preparation, from China’s National Medical Products Administration.With the recent approval, the medical aesthetic company will be able to sell Letybo 100 and 50 units in China. It entered the Chinese botulinum t
The National Institute of Biological Resources (NIBR) said it has licensed out an extract from a native plant, Cyperus flavidus, which has skin cell-protecting effects from environmental pollutants, to local cosmetics companies. The state-funded institute signed technology transfer agreements with C
T&R Biofab, a three-dimensional bio-printing company, has acquired a domestic patent for its functional cell culture medium with a dual structure.The company's tissue culture technology prevents hydrogel deformation caused by the cohesion and maintains high uniformity for a long time during long-ter
Celltrion Group Chairman Seo Jung-jin said Thursday that the company had begun to develop a “cocktail” drug to treat Covid-19 variants and might set out to develop a coronavirus vaccine if needed. In a news conference, Seo said Celltrion is contemplating jumping into the vaccine business under the a
Macrogen said in a public filing Tuesday that it reported 112.6 billion won ($101.9 million) in sales, 7.2 billion won in operating profit, and 90.8 billion won in net profit on a consolidated basis last year.Macrogen’s operating income jumped 899 percent on-year to 7.2 billion won in 2020 from 700
Whether Bridge Biotherapeutics will still work on BBT-877, a treatment candidate for idiopathic pulmonary fibrosis (IPF), after the cancellation of the licensing-out deal with Boehringer Ingelheim last year is drawing attention.BBT-877 inhibits a novel target protein activity, "autotaxin," known to
Celltrion said that the European Commission (EC), which authorizes medicinal products for the EU, has granted sales approval to Yuflyma, a new biosimilar of Abbvie's blockbuster drug, Humira (Ingredient: Adalimumab).The approval comes after the company received a marketing approval recommendation fr
Macrogen has begun to engage in various Covid-19 business by securing the right to sell a Covid-19 diagnostic kit in the global market.On Wednesday, the biotech company announced that its deal with ImmuneMed gave Macrogen the rights to conduct global business with ImmuneMed’s rapid Covid-19 test dev
ToolGen said Tuesday it has signed an agreement with Genexine and its affiliate, GenNBio, to research and commercialize xenotransplantation.Under the agreement, the three companies will co-develop gene-editing pigs for xenotransplantation and establish a cooperative system for clinical trials to spe
Seraxis, a U.S. company in which Medytox has a 25-percent equity stake, has successfully closed $40 million Series C funding The private financing round was led by Eli Lilly, with participation from Frazier Healthcare Partners, Polaris Ventures, JDRF T1D Fund, and other investors, according to Medyt
Korean biotechnology firms are stepping up the construction of manufacturing facilities to jump into Asia’s “viral vector” market, the essential raw material for cell gene therapy. Viral vectors are the key material used to develop treatments, such as “CAR-T cell therapy,” the third-generation antic
Theragen Bio said Monday that it has developed cheaper but more efficient technology to analyze microbiome.The company designed the analytic system by conducting next-generation sequencing (NGS) experiments to prove that an advanced short-read platform can replace the high-priced, long-read sequenci
Humedix said Friday it has taken out a domestic patent for nanoemulsion that contains liposome capturing idebenone, an antiaging composition.The patented material maximizes the use of idebenone, known for antiaging, moisturizing and wrinkle-improving effects by stimulating collagen synthesis, the co
SK Bioscience said it has begun conducting clinical studies on two Covid-19 vaccine candidates.The company is taking a dual-track strategy, focusing on contract manufacturing of a global pharmaceutical firm’s vaccine and the other developing its vaccine with its platform technology.Especially after
Samsung Bioepis' biosimilar sales in the European Union surpassed $795 million in 2020.According to Biogen's earnings report, Samsung Bioepis' marketing partner in the EU, the sales of the Korean drugmaker’s three biosimilar products – Benepali, Flixabi, and Imraldi-totaled $795.8 million last year,
Roche Korea Co., a bio healthcare firm, said Tuesday that FutureProofing Healthcare, a medical data collaborative initiative formed by 15 medical professionals in the Asia-Pacific region, has developed Asia-Pacific Personalized Health Index. The new health index is the industry’s first data-based po
Celltrion said Monday that Health Canada has given the go-ahead for Remsima SC, a Remicade biosimilar that treats rheumatoid arthritis.With the approval, Celltrion Healthcare, responsible for the company's overseas distribution and marketing, plans to establish an offshoot in Canada and sell Remsima
“My experience of connecting with society through the Korea Biotechnology Industry Organization (Korea BIO) was very valuable in my life. I am always grateful to the employees I have worked with at the Korea BIO. I would like to thank our member companies and all those who love the biotech industry.
Samsung Biologics said Wednesday that it recorded sales of 1.1 trillion won ($995.9 million) in 2020, up 66 percent from 2019. The company also registered 292.8 billion won in operating profit, up a drastic 219.3 percent over the cited period."The company has managed to exceed 1 trillion won in annu